» Articles » PMID: 11442493

Identification of Novel FLT-3 Asp835 Mutations in Adult Acute Myeloid Leukaemia

Overview
Journal Br J Haematol
Specialty Hematology
Date 2001 Jul 10
PMID 11442493
Citations 109
Authors
Affiliations
Soon will be listed here.
Abstract

Genomic DNA from 97 cases of adult de novo acute myeloid leukaemia (AML) was screened using polymerase chain reaction (PCR) and conformation-sensitive gel electrophoresis (CSGE) for FLT3 exon 20 mutations. Initial sequencing of four cases, representing the spectrum of CSGE abnormalities, revealed changes affecting codon Asp835 in three cases and also an intron 20 A to G change. In order to identify all possible Asp835 alterations, as well as the frequency of the intronic change nucleotide 2541 + 57 A-->G, the patient PCR products were digested with EcoRV and NlaIII respectively. Seven cases (7.2%) possessed a mutation affecting Asp835; these were identified, following DNA sequencing, as Asp835Tyr (n = 5), Asp835His (n = 1) and Asp835del (n = 1). Alterations affecting Asp835 were not found in 80 normal control DNA samples. In contrast, the nucleotide 2541 + 57 A-->G change was shown to be a polymorphism, with an allelic frequency of 0.24 for the G and 0.76 for the A allele. This study reports, for the first time, point mutations in the human FLT3 gene that, because of their homology with other class III receptor tyrosine kinase mutations, probably result in constitutive activation of the receptor.

Citing Articles

[Efficacy and safety of gilteritinib combined with chemotherapy in newly diagnosed FLT3-mutated acute myeloid leukemia].

Lei Y, Zhao X, Hong M, Liu W, Sun Q, Qian S Zhonghua Xue Ye Xue Za Zhi. 2025; 45(12):1129-1133.

PMID: 39765355 PMC: 11886698. DOI: 10.3760/cma.j.cn121090-20240615-00224.


The Impact of Gilteritinib on Overall Survival of Adult Patients with FLT3 Positive Acute Myeloid Leukemia: A Systematic Review.

Gupta S, Jose N, Tafuto B Princ Pract Clin Res. 2024; 10(2):47-59.

PMID: 39640233 PMC: 11618817. DOI: 10.21801/ppcrj.2024.102.7.


Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.

Kouidri K, Acker F, Toenges R, Pfaff S, Lindner S, Riemann J Ann Hematol. 2024; 103(12):5387-5393.

PMID: 39589497 PMC: 11695448. DOI: 10.1007/s00277-024-06106-y.


Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials.

Lin W, Chao C, Lin C, Hsu Y, Hsiao S, Weng T Mol Clin Oncol. 2024; 21(6):93.

PMID: 39478693 PMC: 11523226. DOI: 10.3892/mco.2024.2791.


Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory -Mutated AML.

Short N, Daver N, DiNardo C, Kadia T, Nasr L, Macaron W J Clin Oncol. 2024; 42(13):1499-1508.

PMID: 38277619 PMC: 11095865. DOI: 10.1200/JCO.23.01911.